Search for a trial

A PHASE I, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER,
SINGLE- AND MULTIPLE-ASCENDING-DOSE STUDY TO DETERMINE INITIAL SAFETY,
TOLERABILITY, AND PHARMACOKINETICS OF GDC-0134 IN PATIENTS WITH AMYOTROPHIC
LATERAL SCLEROSIS

This study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GDC-0134 in patients with amyotrophic lateral sclerosis (ALS). Safety Objective: To evaluate the safety of single and multiple…

A phase I, double-blind, randomized, placebo-controlled, multicenter, Single- and multiple-ascending-dose study to determine initial safety, Tolerability, and pharmacokinetics of GDC-0134 in patients with amyotrophic Lateral sclerosis

This study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GDC-0134 in patients with amyotrophic lateral sclerosis (ALS).The long term safety and tolerability of up to 48 weeks of GDC-0134 will…